Korean J Obstet Gynecol Search

CLOSE


Korean Journal of Obstetrics & Gynecology 2004;47(11):2209-2212.
Published online November 1, 2004.
Gemcitabine as second-line chemotherapy in patients with recurrent epithelial ovarian cancer: Review of four cases.
Yong Joo Park, Chul Min Lee, Hyung Joo Seo, Hye Joo Lee, Jaung Sun Kim, Ji Kyung Ko, Yong Kyoon Cho, Hoon Choi, Bok Rin Kim, Hong Kyoon Lee
Department of Obstetrics and Gynecology, Inje University, Sanggye Paik Hospital, Seoul, Korea.
Abstract
Adjuvant multiagent chemotherapy with platinum and paclitaxel after optimal cytoreductive surgery decisively improved survival rates of patients with epithelial ovarian carcinoma. However, more than two- thirds of patients with advanced disease will encounter tumor progression, underlining the need for effective second-line strategies. Continued efforts to discover new active agents for the treatment of patients with ovarian carcinoma had identified gemcitabine. Four patients with epithelial ovarian carcinoma, who were treated in Inje University Sanggye Paik Hospital and recurred thereafter received gemcitabine 1,000 mg/m2 as a 30 min intravenous infusion on days 1, 8, and 15, which was repeated every 28 days. The disease progressed in two patients, while one showed stable disease and another reached complete response. One patient expired of disease two months after the completion of therapy. Grade 3 leukopenia was successfully managed using G-CSF. Regrowth of hair lost during previous chemotherapy occurred in all subjects. We report four cases of advanced recurrent ovarian carcinoma which were treated with gemcitabine.
Key Words: Recurrent ovarian carcinoma, Gemcitabine, Second-line chemotherapy


ABOUT
ARTICLE & TOPICS
Article category

Browse all articles >

Topics

Browse all articles >

BROWSE ARTICLES
POLICY
FOR CONTRIBUTORS
Editorial Office
4th Floor, 36 Gangnam-daero 132-gil, Gangnam-gu, Seoul 06044, Korea
Tel: +82-2-3445-2382    Fax: +82-2-3445-2440    E-mail: journal@ogscience.org                

Copyright © 2020 by Korean Society of Obstetrics and Gynecology. All rights reserved.

Developed in M2community

Close layer
prev next